Veradermics (NYSE:MANE) Price Target Raised to $164.00

Veradermics (NYSE:MANE) had its price target hoisted by Needham & Company LLC from $136.00 to $164.00 in a report issued on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other analysts have also recently commented on MANE. Wall Street Zen cut Veradermics from a “hold” rating to a “sell” rating in a report on Sunday, July 12th. Citigroup upped their price objective on shares of Veradermics from $120.00 to $135.00 and gave the company a “buy” rating in a research note on Monday, May 18th. Weiss Ratings started coverage on shares of Veradermics in a research report on Tuesday, May 26th. They set a “sell (d+)” rating for the company. Jefferies Financial Group lifted their target price on shares of Veradermics from $138.00 to $182.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Finally, UBS Group set a $170.00 target price on shares of Veradermics in a report on Wednesday. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $153.00.

Veradermics Stock Up 5.5%

MANE opened at $111.61 on Wednesday. The company has a market cap of $4.66 billion and a price-to-earnings ratio of -84.56. The stock’s 50 day simple moving average is $106.91. Veradermics has a fifty-two week low of $32.00 and a fifty-two week high of $131.24.

Veradermics (NYSE:MANE) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.76).

Veradermics Company Profile

We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation.